CYP2C8*3 was significantly associated with increased risks of severe (grades 3-4) neutropenia (OR<sub>adjusted</sub> 2.11; 95% CI 1.24-3.6; dominant model) and severe thrombocytopenia (OR<sub>adjusted</sub> 4.93; 95% CI 1.69-14.35; recessive model), whereas ABCB1 variant genotypes (OR<sub>adjusted</sub> 2.13; 95% CI 1.32-3.42), in association with CYP2C8*3 wild type (GG) (OR<sub>adjusted</sub> 1.93; 95% CI 1.17-3.19), were predictive of severe fatigue.
CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.